Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) Interest & Investment Income (2016 - 2025)

Historic Interest & Investment Income for Intellia Therapeutics (NTLA) over the last 10 years, with Q3 2025 value amounting to $6.7 million.

  • Intellia Therapeutics' Interest & Investment Income fell 4461.31% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.4 million, marking a year-over-year decrease of 3280.95%. This contributed to the annual value of $47.8 million for FY2024, which is 406.37% down from last year.
  • As of Q3 2025, Intellia Therapeutics' Interest & Investment Income stood at $6.7 million, which was down 4461.31% from $7.4 million recorded in Q2 2025.
  • In the past 5 years, Intellia Therapeutics' Interest & Investment Income registered a high of $12.7 million during Q3 2023, and its lowest value of $211000.0 during Q2 2021.
  • For the 5-year period, Intellia Therapeutics' Interest & Investment Income averaged around $6.9 million, with its median value being $7.4 million (2025).
  • Its Interest & Investment Income has fluctuated over the past 5 years, first plummeted by 8228.66% in 2021, then surged by 211851.85% in 2023.
  • Quarter analysis of 5 years shows Intellia Therapeutics' Interest & Investment Income stood at $503000.0 in 2021, then soared by 964.41% to $5.4 million in 2022, then soared by 132.7% to $12.5 million in 2023, then dropped by 14.67% to $10.6 million in 2024, then crashed by 36.85% to $6.7 million in 2025.
  • Its last three reported values are $6.7 million in Q3 2025, $7.4 million for Q2 2025, and $8.6 million during Q1 2025.